According to our latest study on “Sterile Compounding Pharmacies Market Analysis and Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product and Route of Administration and Geography. The market is estimated to grow from US$ 3,968.70 million in 2021 to US$ 6,198.59 million by 2028; it is estimated to grow at a CAGR of 6.6% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.
Check for the sample here -
https://www.theinsightpartners.com/sample/TIPRE00026302/
The injectable medications and infusions segments of the market for sterile compounding pharmacies are divided based on product. During the period 2021–2028, the injectable medicine sector would hold a greater market share.
The final report will add the analysis of the Impact of Covid-19 in this report Sterile Compounding Pharmacies Market.
The COVID-19 pandemic has had a detrimental effect on the world Sterile Compounding Pharmacies market because of the closure of manufacturing facilities, the increase in raw material prices, the manpower shortage, the disruption of supply chains, and the state of the economy. The industries that were most significantly damaged by the pandemic, including construction, paints and coatings, cosmetics, and construction, are those that utilise Sterile Compounding Pharmacies the most. Therefore, a considerable decrease in residential construction projects as a result of the financial crisis and a dropping trend from end-use sectors as a result of the pandemic have seriously hindered the market's growth.
Some of the companies competing in The Sterile Compounding Pharmacies Market are
- Fagron, Inc.
- Triangle Compounding Pharmacy
- B. Braun Melsungen AG
- PharMedium Healthcare Holdings, Inc.
- Fresenious Kabi AG
- Avella Specialty Pharmacy
- Pencol Compounding Pharmacy
- Pavilion Compounding Pharmacy, LLC.
- Pace Pharmacy
- SandsRx
Due to a lack of pharmaceutical supplies during the early months of the COVID-19 epidemic, drug demand increased. The Alliance for Compounding Pharmacies advocated a measure in Congress that focuses on broadening the circumstances under which 503As can help with shortages in order to address this issue of scarcity. Implementing 503As (503A is a traditional compounding pharmacy that compounds in relation to patient-specific prescriptions and complies with USP guidelines) and 503Bs (503B pharmacies are the only compounding pharmacies that are able to provide office-use (or office-administered medications) for supporting compounding practices are two examples of this. For the purpose of keeping records, 503Bs may mass-produce and distribute formulations to organizations like hospitals without a prescription for a particular patient.
ABOUT US:
The Insight Partners is a one stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact US:
If you have any queries about this report or would like further information, please contact us:
North America: +1 646 491 9876
Asia-Pacific: +91 20 6727 8686
Email: sales@theinsightpartners.com
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek